Importance of the field: Type 2 diabetes is typically associated with insulin resistance and dysfunction of insulin-secreting pancreatic beta-cells. Addressing these defects often requires therapy with a combination of differently acting antidiabetic agents. A potential novel combination in development brings together the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin with the thiazolidinedione pioglitazone into a fixed-dose single-tablet combination. The former component acts mainly to increase prandial insulin secretion; the latter improves insulin sensitivity.
ASJC Scopus subject areas
- Pharmacology (medical)
Bailey, C. J., Green, B., & Flatt, P. R. (2010). Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Expert opinion on investigational drugs, 19(8), 1017-1025. https://doi.org/10.1517/13543784.2010.505235